Lipocine Inc (LPCN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 106.77 is considered Overvalued compared with the five-year average of -4.51. The fair price of Lipocine Inc (LPCN) is between 1.98 to 4.02 according to relative valuation method. Compared to the current price of 8.84 USD , Lipocine Inc By Overvalued By 120.13%.

Relative Value

Fair Zone

1.98-4.02

Current Price：8.84

120.13%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lipocine Inc (LPCN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lipocine Inc (LPCN) has a current Price-to-Book (P/B) ratio of 3.07. Compared to its 3-year average P/B ratio of 1.04, the current P/B ratio is approximately 196.11% higher. Relative to its 5-year average P/B ratio of 1.59, the current P/B ratio is about 92.58% higher. Lipocine Inc (LPCN) has a Forward Free Cash Flow (FCF) yield of approximately -11.59%. Compared to its 3-year average FCF yield of -37.23%, the current FCF yield is approximately -68.86% lower. Relative to its 5-year average FCF yield of -26.21%, the current FCF yield is about -55.77% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LPCN competitors is 59.94, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN.O) exhibits a P/S ratio of 106.77, which is 78.13% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LPCN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LPCN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LPCN currently overvalued or undervalued?

What is Lipocine Inc (LPCN) fair value?

LPCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lipocine Inc (LPCN) is between 1.98 to 4.02 according to relative valuation method.

How does LPCN's valuation metrics compare to the industry average?

The average P/S ratio for LPCN's competitors is 59.94, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN) exhibits a P/S ratio of 106.77, which is 78.13% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Lipocine Inc (LPCN) as of Mar 03 2026?

As of Mar 03 2026, Lipocine Inc (LPCN) has a P/B ratio of 3.07. This indicates that the market values LPCN at 3.07 times its book value.

What is the current FCF Yield for Lipocine Inc (LPCN) as of Mar 03 2026?

As of Mar 03 2026, Lipocine Inc (LPCN) has a FCF Yield of -11.59%. This means that for every dollar of Lipocine Inc's market capitalization, the company generates -11.59 cents in free cash flow.

What is the current Forward P/E ratio for Lipocine Inc (LPCN) as of Mar 03 2026?

As of Mar 03 2026, Lipocine Inc (LPCN) has a Forward P/E ratio of -3.36. This means the market is willing to pay $-3.36 for every dollar of Lipocine Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lipocine Inc (LPCN) as of Mar 03 2026?

As of Mar 03 2026, Lipocine Inc (LPCN) has a Forward P/S ratio of 106.77. This means the market is valuing LPCN at $106.77 for every dollar of expected revenue over the next 12 months.

LPCN Valuation